[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-254204-105":53,"doc-detail-254204-en":126},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":119,"head_meta":121,"extra_data":123,"updated_unix":125},105,"en","iglc-and-aap-joint-rfp-to-improve-pediatric-adhd-care","IGLC与美国儿科学会联合改善儿童ADHD诊疗的招标书 - 提案征集（RFP）","","Request for Proposals (RFP)邀请美国儿科学会（AAP）与Pfizer Independent Grants for Learning & Change（IGLC）合作伙伴，围绕提升儿童注意力缺陷/多动障碍（ADHD）诊疗质量开展创新策略试点。入选资助对象最高可获150,000美元，用于基于AAP关于ADHD诊断、评估与治疗的临床实践指南进行学习与变革。文件强调独立资助项目由受助机构全权负责，并要求以可衡量的结果与影响提交报告。",{"@graph":63,"@context":118},[64,80,101],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":11,"@type":70,"position":76},"https://docshare.wps.com/template/presentations/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/iglc-and-aap-joint-rfp-to-improve-pediatric-adhd-care/254204/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/iglc-and-aap-joint-rfp-to-improve-pediatric-adhd-care/254204.png","ImageObject",442,249,{"name":88,"@type":89},"Melati","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-11-01","2026-09-13",true,{"@type":98,"interactionType":99,"userInteractionCount":15},"InteractionCounter",{"@type":100},"ViewAction",{"@type":102,"mainEntity":103},"FAQPage",[104,110,114],{"name":105,"@type":106,"acceptedAnswer":107},"本RFP的资助重点是什么？","Question",{"text":108,"@type":109},"资助重点是通过创新策略改善儿童ADHD的诊疗质量，并基于AAP关于ADHD诊断、评估与治疗的临床实践指南验证可衡量的学习与变革。","Answer",{"name":111,"@type":106,"acceptedAnswer":112},"最高资助金额是多少？",{"text":113,"@type":109},"选定的受助机构最高可获150,000美元。",{"name":115,"@type":106,"acceptedAnswer":116},"Pfizer Independent Grants for Learning & Change（IGLC）“Independent”意味着什么？",{"text":117,"@type":109},"“Independent”表示由Pfizer资助的项目完全由受助机构负责；Pfizer不影响项目任何方面，仅要求提供结果与影响的报告以便公开分享。","https://schema.org",{"og:url":78,"og:type":120,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":122,"canonical":78},"index,follow",{"doc_id":124,"site_id":56},254204,1791726073,{"code":4,"msg":5,"data":127},{"doc_id":124,"user_id":128,"nickname":88,"user_avatar":129,"doc_module":9,"category_id":8,"category_name":11,"doc_title":59,"doc_description":61,"doc_content":130,"file_id":131,"file_url":132,"file_type":133,"file_size":134,"view_count":15,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":135,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":141},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Improving Pediatric ADHD Care – Innovative Implementation of a National Guideline  \nRequest for Proposals (RFP)  \nThe American Academy of Pediatrics (AAP) and  \nPfizer Independent Grants for Learning & Change (IGLC)  \nApril 27, 2017  \nI. Background  \nThe American Academy of Pediatrics (AAP) and Pfizer are collaborating to offer a new grant opportunity focused on improving care for children with Attention Deficit Hyperactivity Disorder (ADHD) . Selected grantees will be awarded up to $150,000 to test innovative strategies to improve care based on the AAP’s Clinical Practice Guideline for the Diagnosis, Evaluation and Treatment of ADHD in Children and Adolescents (AAP ADHD guideline) .  \nThe mission of Pfizer Independent Grants for Learning & Change (IGLC) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies.“Independent” means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.  \nThe mission of the AAP is to attain optimal physical, mental, and social health and well-being for all infants, children, adolescents and young adults. ADHD is the most common childhood neurobehavioral disorder, affecting 11% of all children aged 4-17 in the United States. 1,2,3 The disorder can continue into adolescence and adulthood, causing prolonged academic, conduct, social and mental health problems.4  \nIn 2011, the AAP issued a comprehensive update of its ADHD clinical practice guideline. The revised guideline emphasizes proper evaluation and diagnosis, including documentation of impairment in more than one major setting; assessment for co-existing conditions; recognition that children with ADHD should be treated as children and youth with special health care needs and managed according to the principles of the chronic care model and medical home; and age-appropriate treatment, including proper titration of medication and behavior therapy.2  \nHowever, despite excellent intentions and pockets of superb care, a major opportunity still exists to improve care for children with ADHD and their families, as much care is still delivered in ways that contrast sharply with AAP recommendations.5 In a 2014 article, Epstein, et al. reported that parent-and teacher-rating scales were used during ADHD assessment with only about half of patients (56 . 7% and  \n55. 5%, respectively) . The use of DSM-IV criteria was documented in 70.4% of patients. 93.4% of patients with ADHD were prescribed medication, but only 13.0% of patients were receiving or recommended behavior therapy. Less than half of children (47 .4%) had a follow-up contact from their provider via visitor phone within the first month, a practice useful for medication titration and monitoring of side effects. Amongst children with any follow-up contact, average time from medication initiation to first follow-up was 72.4 days; per the AAP ADHD guideline, stimulant medications can be titrated on a 3-to 7-day basis.2 Furthermore, parent-and teacher-ratings were rarely collected to monitor treatment response or side effects (10 .8% and 7. 5%, respectively) . Most variability in pediatrician-delivered ADHD care was accounted for at the patient level; however, pediatricians and practices also accounted for significant variability on specific ADHD care behaviors.2,5  \nThe AAP believes that increased exposure to the guideline, coupled with implementation support, will help pediatricians improve care for children with ADHD. The AAP tested this hypothesis from December 2015 to January 2017 through its Chapter Quality Network (CQN) ADHD pilot project.  \nFor the CQN ADHD pilot project, the national AAP partnered with six AAP state chapters to lead teams from outpatient pediatric practices as they fo","cbCaieV0RZxE0evP","https://ap.wps.com/l/cbCaieV0RZxE0evP","pdf",806499,19,"English","# I. Background\n## AAP and IGLC Collaboration\n## ADHD Burden and Guideline Update\n## Gap Between Recommendations and Practice\n## CQN ADHD Pilot Project and Key Findings\n## RFP Purpose and Intended Innovation","[{\"question\":\"本RFP的资助重点是什么？\",\"answer\":\"资助重点是通过创新策略改善儿童ADHD的诊疗质量，并基于AAP关于ADHD诊断、评估与治疗的临床实践指南验证可衡量的学习与变革。\"},{\"question\":\"最高资助金额是多少？\",\"answer\":\"选定的受助机构最高可获150,000美元。\"},{\"question\":\"Pfizer Independent Grants for Learning \\u0026 Change（IGLC）“Independent”意味着什么？\",\"answer\":\"“Independent”表示由Pfizer资助的项目完全由受助机构负责；Pfizer不影响项目任何方面，仅要求提供结果与影响的报告以便公开分享。\"}]","IGLC与美国儿科学会联合改善儿童ADHD诊疗的招标书 - 提案征集（RFP） | PDF",1789276471,7]